Page 70 - Read Online

Page 12 of 14 Milluzzo et al. Metab Target Organ Damage 2024;4:5 https://dx.doi.org/10.20517/mtod.2023.43

Conflicts of interest
Agostino Milluzzo is a Junior Editorial Board Member of the journal Metabolism and Target Organ
Damage. Other authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2024.

REFERENCES

1. Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and
projections for 2045. Diabetes Res Clin Pract 2022;183:109119. DOI
2. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin 2021;71:209-49. DOI
3. Gallo M, Muscogiuri G, Felicetti F, et al. Adverse glycaemic effects of cancer therapy: indications for a rational approach to cancer
patients with diabetes. Metabolism 2018;78:141-54. DOI
4. Milluzzo A, Vigneri P, Martorana F, Vigneri R, Sciacca L. Type 2 diabetes and cancer: problems and suggestions for best patient
management. Explor Med 2020;1:184-204. DOI
5. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010;33:1674-85. DOI
PubMed PMC
6. Vella V, Milluzzo A, Scalisi NM, Vigneri P, Sciacca L. Insulin receptor isoforms in cancer. Int J Mol Sci 2018;19:3615. DOI
PubMed PMC
7. Cignarelli A, Genchi VA, Caruso I, et al. Diabetes and cancer: pathophysiological fundamentals of a 'dangerous affair'. Diabetes Res
Clin Pract 2018;143:378-88. DOI
8. Sciacca L, Scalisi NM, Cassarino MF, et al. Different effects of the insulin receptor isoforms on 32D cell growth and differentiation. J
Diabetes Endocrinol Metab Disord 2017:1-9. DOI
9. Pinheiro LC, Soroka O, Kern LM, Leonard JP, Safford MM. Diabetes care management patterns before and after a cancer diagnosis: a
SEER-Medicare matched cohort study. Cancer 2020;126:1727-35. DOI PubMed
10. Milluzzo A, Tumminia A, Vella V, et al. Short-term adverse effects of anticancer drugs in patients with type 2 diabetes. J Chemother
2019;31:150-9. DOI
11. ElSayed NA, Aleppo G, Aroda VR, et al. 12. retinopathy, neuropathy, and foot care: standards of care in diabetes-2023. Diabetes Care
2023;46:S203-15. DOI PubMed PMC
12. Takao T, Suka M, Yanagisawa H, Matsuyama Y, Iwamoto Y. Predictive ability of visit-to-visit variability in HbA1c and systolic blood
pressure for the development of microalbuminuria and retinopathy in people with type 2 diabetes. Diabetes Res Clin Pract
2017;128:15-23. DOI PubMed
13. Jampol LM, Glassman AR, Sun J. Evaluation and care of patients with diabetic retinopathy. N Engl J Med 2020;382:1629-37. DOI
PubMed
14. Tumminia A, Milluzzo A, Carrubba N, Vinciguerra F, Baratta R, Frittitta L. Excessive generalized and visceral adiposity is associated
with a higher prevalence of diabetic retinopathy in Caucasian patients with type 2 diabetes. Nutr Metab Cardiovasc Dis 2023:Online
ahead of print. DOI PubMed
15. Milluzzo A, Barchitta M, Maugeri A, Agodi A, Sciacca L. Body mass index is related to short term retinal worsening in type 2
diabetes patients treated with anticancer drugs. Minerva Endocrinol 2022:Online ahead of print. DOI PubMed
16. Milluzzo A, Maugeri A, Barchitta M, Sciacca L, Agodi A. Epigenetic mechanisms in type 2 diabetes retinopathy: a systematic review.
Int J Mol Sci 2021;22:10502. DOI PubMed PMC
17. Milluzzo A, Barchitta M, Maugeri A, et al. Do nutrients and nutraceuticals play a role in diabetic retinopathy? Nutrients 2022;14:4430.
DOI PubMed PMC
18. Renouf DJ, Velazquez-Martin JP, Simpson R, Siu LL, Bedard PL. Ocular toxicity of targeted therapies. J Clin Oncol 2012;30:3277-
86. DOI PubMed
19. Liu CY, Francis JH, Brodie SE, et al. Retinal toxicities of cancer therapy drugs: biologics, small molecule inhibitors, and
chemotherapies. Retina 2014;34:1261-80. DOI